Clinical Trials
81 trialsNCT07580833 2026-05-12
A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors
Health Hope Pharma
Phase 1 Not yet recruiting
NCT05307705 2026-04-20
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02390427 2026-04-09
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07216105 2026-04-07
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT03725436 2026-03-16
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06513364 2026-01-20
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Beijing Wehand-Bio Pharmaceutical Co., Ltd
Phase 1 Completed
NCT04556773 2025-12-17
DB-08
AstraZeneca
Phase 1 Active not recruiting
NCT03595059 2025-12-10
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
Phase 1 Completed
NCT03716180 2025-09-22
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02608216 2025-09-03
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
University of Pennsylvania
Phase 1 Active not recruiting
NCT03858322 2025-08-11
'ADVANCE' (A Pilot Trial)
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02776917 2025-08-07
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
University of California, San Diego
Phase 1 Completed
NCT04778839 2025-08-06
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
Phase 1 Recruiting
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT03165955 2025-03-12
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Health Hope Pharma
Phase 1 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03800836 2024-10-30
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT02672475 2023-11-22
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT05519059 2023-11-22
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Completed
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT00003927 2023-07-05
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT04252768 2023-03-22
AIPAC-002
Immutep S.A.S.
Phase 1 Withdrawn
NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
NCT02474173 2022-11-04
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT04261218 2022-07-20
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer
Translational Research in Oncology
Phase 1 Completed
NCT02569489 2022-07-18
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
HUYABIO International, LLC.
Phase 1 Withdrawn
NCT04762901 2022-04-26
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Wake Forest University Health Sciences
Phase 1 Withdrawn
NCT02824575 2022-04-04
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Montefiore Medical Center
Phase 1 Terminated
NCT03600090 2022-03-31
Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Phase 1 Completed
NCT00788931 2020-12-19
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
Novartis
Phase 1 Completed
NCT02051751 2020-12-08
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Novartis
Phase 1 Completed
NCT00367471 2020-09-09
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Novartis
Phase 1 Completed
NCT01973309 2020-09-09
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
Mereo BioPharma
Phase 1 Completed
NCT01249443 2020-07-29
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
Phase 1 Terminated
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT01320592 2020-04-08
PD0332991/Paclitaxel in Advanced Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02366949 2020-04-07
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
Bayer
Phase 1 Completed
NCT02069158 2019-05-21
IOSI-NDU-001
Oncology Institute of Southern Switzerland
Phase 1 Completed
NCT02138812 2018-10-12
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Bayer
Phase 1 Terminated
NCT03285607 2018-08-16
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Washington University School of Medicine
Phase 1 Withdrawn
NCT02060253 2018-06-14
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00707707 2018-03-06
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
AstraZeneca
Phase 1 Completed
NCT01862081 2017-11-28
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
Genentech, Inc.
Phase 1 Completed
NCT00388076 2017-11-17
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
GlaxoSmithKline
Phase 1 Completed
NCT01918254 2017-09-12
A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein
Hoffmann-La Roche
Phase 1 Completed
NCT01263145 2017-08-25
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed